DPH — Dechra Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- £4.40bn
- £4.83bn
- £761.50m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 482 | 515 | 608 | 682 | 762 |
Cost of Revenue | |||||
Gross Profit | 278 | 292 | 346 | 385 | 430 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 444 | 465 | 521 | 600 | 777 |
Operating Profit | 38 | 49.7 | 86.8 | 82 | -15.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 27.8 | 40.9 | 74 | 77.6 | -36.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | 20.9 | 33.9 | 55.5 | 58.2 | -27.9 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 30.9 | 33.9 | 55.5 | 58.2 | -27.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 30.9 | 33.9 | 55.5 | 58.2 | -27.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.598 | 0.586 | 0.726 | 0.96 | 0.575 |
Dividends per Share |